Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fipexide SCHEMBL467102 | 0.99 | CYP3A4 (1.00) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL5056093 | 0.94 | LMNA (0.90) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL5066354 | 0.87 | LMNA (0.76) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| Fipexide SCHEMBL7617055 | 0.85 | LMNA (0.73) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL7155864 | 0.84 | LMNA (0.71) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL24254289 | 0.83 | MAPT (1.00) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL29394551 | 0.83 | MAPT (1.00) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL5059170 | 0.83 | LMNA (0.71) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL5064003 | 0.82 | LMNA (0.69) | LMNACYP3A4ABCB11CYP1A2ADRA2A | |
| SCHEMBL5059273 | 0.82 | CYP3A4 (0.69) | LMNACYP3A4ABCB11CYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250311689-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-10-09 | — | — | US | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| US-11819535-B2 | Composition and methods for regulating extracellular matrix accumulation | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-21 | — | — | US | claimed |
| WO-2023056236-A1 | SEEDLING GERMINATION AND GROWTH CONDITIONS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230074763-A1 | IDENTIFICATION OF HOST-TARGETING MODULATORS OF BACTERIAL UPTAKE AND ASSAY FOR QUANTIFYING INTRACELLULAR BACTERIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-03-09 | — | — | US | claimed |
| EP-3153014-B1 | AGENT FOR INDUCING PLANT CALLUS AND METHOD FOR INDUCING PLANT CALLUS | RIKEN (JP) | 2020-12-30 | — | — | EP | claimed |
| US-10676711-B2 | Agent for inducing callus and method for inducing callus | RIKEN (JP) | 2020-06-09 | — | — | US | claimed |
| EP-0804239-B1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1999-09-15 | — | — | EP | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0804239-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | Riga, Dan (RO) | 1997-11-05 | — | — | EP | claimed |
| CN-1156410-A | Anti-stress, anti-injury and anti-aging medicine and production method thereof | RIGA D (RO) | 1997-08-06 | — | — | CN | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0090202-B1 | PROCESS FOR PREPARING P.CHLOROPHENOXYACETYL-PIPERONYLPIPERAZINE | RAVIZZA S.p.A. (IT) | 1986-12-30 | — | — | EP | claimed |
| EP-0090203-B1 | PROCESS FOR PREPARING P.CHLOROPHENOXYACETYL-PIPERONYLPIPERAZINE | RAVIZZA S.p.A. (IT) | 1986-11-12 | — | — | EP | claimed |
| US-4225714-A | Process for preparing p-chlorophenoxy-acetyl-piperonylpiperazine hydrochloride | FARMACEUTICI GEYMONAT SUD S.P.A. (IT) | 1980-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | LMNA 4763/4885CYP3A4 20/4885ABCB11 263/4885 |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | LMNA 4763/4885CYP3A4 20/4885ABCB11 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.